



NDA 022071/S-006

**SUPPLEMENT APPROVAL**

Novartis Pharmaceuticals Corporation  
Attention: Raffy Chilingerian, DMH, MS, BBA, CCRA  
RBRM, Drug Regulatory Affairs  
One Health Plaza  
East Hanover, NJ 07936-1080

Dear Mr. Chilingerian:

Please refer to your Supplemental New Drug Application (sNDA) dated April 29, 2011 received May 11, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lamisil (terbinafine hydrochloride) Oral Granules, 125 mg and 187.5 mg.

We acknowledge receipt of your amendment dated June 13, 2011.

This "Prior Approval" supplemental new drug application provides for updates to the **Postmarketing Experience** subsection (6.2), **Drug-Drug Interactions** subsection (7.1) and **PATIENT COUNSELING INFORMATION** section (17) of the package insert.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Matthew White, Regulatory Project Manager, at (301) 796-4997.

Sincerely,

*{See appended electronic signature page}*

Tatiana Oussova, M.D., M.P.H.  
Deputy Director for Safety  
Division of Dermatology and Dental Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

TATIANA OUSSOVA  
11/04/2011